Effect of pramipexole in treatment of resistant restless legs syndrome

Siong Chi Lin, Joseph Kaplan, Charles Dwayne Burger, Paul A. Fredrickson

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Objective: To report the results of an open-label trial with a dopaminergic agent, pramipexole, in patients with treatment-resistant restless legs syndrome (RLS). Material and Methods: We studied the response to pramipexole in a consecutive series of 16 patients with symptomatic RLS who had previously experienced failure with other dopaminergic therapies. Patients assessed their posttreatment change in symptoms of RLS on a visual analog scale and indicated drug-related side effects with use of a checklist. Results: With a mean dose of pramipexole of 0.3 mg, most patients reported clinically significant improvement. From 2 to 3 months after initiation of pramipexole therapy, nocturnal leg restlessness, involuntary leg movements, and insomnia had decreased in 12, 10, and 11 patients, respectively. The most frequent adverse effects were fatigue and stiffness, which occurred in a third of the patients. Overall, the drug was well tolerated. Conclusion: On the basis of these findings, we propose that pramipexole, a D2 subgroup receptor agonist, is an effective agent for treatment of RLS.

Original languageEnglish (US)
Pages (from-to)497-500
Number of pages4
JournalMayo Clinic Proceedings
Volume73
Issue number6
StatePublished - 1998

Fingerprint

Restless Legs Syndrome
Leg
Therapeutics
Psychomotor Agitation
Dopamine Agents
Dyskinesias
Sleep Initiation and Maintenance Disorders
Drug-Related Side Effects and Adverse Reactions
Checklist
Visual Analog Scale
Fatigue
pramipexole
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lin, S. C., Kaplan, J., Burger, C. D., & Fredrickson, P. A. (1998). Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clinic Proceedings, 73(6), 497-500.

Effect of pramipexole in treatment of resistant restless legs syndrome. / Lin, Siong Chi; Kaplan, Joseph; Burger, Charles Dwayne; Fredrickson, Paul A.

In: Mayo Clinic Proceedings, Vol. 73, No. 6, 1998, p. 497-500.

Research output: Contribution to journalArticle

Lin, SC, Kaplan, J, Burger, CD & Fredrickson, PA 1998, 'Effect of pramipexole in treatment of resistant restless legs syndrome', Mayo Clinic Proceedings, vol. 73, no. 6, pp. 497-500.
Lin, Siong Chi ; Kaplan, Joseph ; Burger, Charles Dwayne ; Fredrickson, Paul A. / Effect of pramipexole in treatment of resistant restless legs syndrome. In: Mayo Clinic Proceedings. 1998 ; Vol. 73, No. 6. pp. 497-500.
@article{2834538e3db34487af1177480a36f5e6,
title = "Effect of pramipexole in treatment of resistant restless legs syndrome",
abstract = "Objective: To report the results of an open-label trial with a dopaminergic agent, pramipexole, in patients with treatment-resistant restless legs syndrome (RLS). Material and Methods: We studied the response to pramipexole in a consecutive series of 16 patients with symptomatic RLS who had previously experienced failure with other dopaminergic therapies. Patients assessed their posttreatment change in symptoms of RLS on a visual analog scale and indicated drug-related side effects with use of a checklist. Results: With a mean dose of pramipexole of 0.3 mg, most patients reported clinically significant improvement. From 2 to 3 months after initiation of pramipexole therapy, nocturnal leg restlessness, involuntary leg movements, and insomnia had decreased in 12, 10, and 11 patients, respectively. The most frequent adverse effects were fatigue and stiffness, which occurred in a third of the patients. Overall, the drug was well tolerated. Conclusion: On the basis of these findings, we propose that pramipexole, a D2 subgroup receptor agonist, is an effective agent for treatment of RLS.",
author = "Lin, {Siong Chi} and Joseph Kaplan and Burger, {Charles Dwayne} and Fredrickson, {Paul A.}",
year = "1998",
language = "English (US)",
volume = "73",
pages = "497--500",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - Effect of pramipexole in treatment of resistant restless legs syndrome

AU - Lin, Siong Chi

AU - Kaplan, Joseph

AU - Burger, Charles Dwayne

AU - Fredrickson, Paul A.

PY - 1998

Y1 - 1998

N2 - Objective: To report the results of an open-label trial with a dopaminergic agent, pramipexole, in patients with treatment-resistant restless legs syndrome (RLS). Material and Methods: We studied the response to pramipexole in a consecutive series of 16 patients with symptomatic RLS who had previously experienced failure with other dopaminergic therapies. Patients assessed their posttreatment change in symptoms of RLS on a visual analog scale and indicated drug-related side effects with use of a checklist. Results: With a mean dose of pramipexole of 0.3 mg, most patients reported clinically significant improvement. From 2 to 3 months after initiation of pramipexole therapy, nocturnal leg restlessness, involuntary leg movements, and insomnia had decreased in 12, 10, and 11 patients, respectively. The most frequent adverse effects were fatigue and stiffness, which occurred in a third of the patients. Overall, the drug was well tolerated. Conclusion: On the basis of these findings, we propose that pramipexole, a D2 subgroup receptor agonist, is an effective agent for treatment of RLS.

AB - Objective: To report the results of an open-label trial with a dopaminergic agent, pramipexole, in patients with treatment-resistant restless legs syndrome (RLS). Material and Methods: We studied the response to pramipexole in a consecutive series of 16 patients with symptomatic RLS who had previously experienced failure with other dopaminergic therapies. Patients assessed their posttreatment change in symptoms of RLS on a visual analog scale and indicated drug-related side effects with use of a checklist. Results: With a mean dose of pramipexole of 0.3 mg, most patients reported clinically significant improvement. From 2 to 3 months after initiation of pramipexole therapy, nocturnal leg restlessness, involuntary leg movements, and insomnia had decreased in 12, 10, and 11 patients, respectively. The most frequent adverse effects were fatigue and stiffness, which occurred in a third of the patients. Overall, the drug was well tolerated. Conclusion: On the basis of these findings, we propose that pramipexole, a D2 subgroup receptor agonist, is an effective agent for treatment of RLS.

UR - http://www.scopus.com/inward/record.url?scp=0031746327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031746327&partnerID=8YFLogxK

M3 - Article

C2 - 9621854

AN - SCOPUS:0031746327

VL - 73

SP - 497

EP - 500

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -